多个连接体的同时分子对接和动态方法来研究在ErbB4氨酸酸化上库尔库明类型的协同抑制作用
La Ode Aman1, Netty Ino Ischak2, Teti Sutriyati Tuloli1
1Department of Pharmacy, Faculty of Sport and Health, Universitas Negeri Gorontalo, Gorontalo, Indonesia.
Research in pharmaceutical sciences
|February 6, 2025
概括
两种新型化合物,AC01和AC02,显示出作为ErbB4抑制剂的潜力. 计算研究表明,它们可以单独或与拉帕提尼布 (FMM) 结合起作用作为抗癌剂.
科学领域:
- 计算化学是一种计算化学.
- 分子建模分子建模
- 药物发现 药物发现
背景情况:
- 拉帕提尼布 (FMM) 和5-甲 (5-FU) 是已知的抗癌药物.
- FMM针对ErbB4的铁酸化,而5-FU则抑制细胞增殖.
- ErbB4 是癌症治疗中的一个关键目标.
研究的目的:
- 调查AC01和AC02的ErbB4抑制潜力.
- 评估AC01和AC02作为单一疗法和与FMM结合使用.
- 为了比较AC01/AC02-FMM组合的疗效与FMM-5-FU参考.
主要方法:
- 计算模拟包括单个和同时的联结对接.
- 用于结合自由能计算的分子动力学模拟.
- 使用AutoDockTools和gmx_MMPBSA进行分析.
主要成果:
- 5-FU显示最低的结合亲和力;FMM显示最高.
- AC01和AC02与ErbB4结合,其重叠位置与FMM-5-FU.
- 与5-FU不同的是,AC01和AC02占据了ErbB4激活循环.
- 在AC02中,与AC01.01相比,与ErbB4的结合略强一些.
结论:
- 作为抗癌药物候选药物,AC01和AC02显示出前景.
- 这些化合物具有抑制ErbB4的潜力.
- AC01和AC02可以与FMM协同作用,以增强抗癌效果.
相关概念视频
Allosteric Regulation
57.5K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.5K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Ligand Binding and Linkage
4.7K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.7K
Cooperative Allosteric Transitions
7.8K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.8K
Receptor Tyrosine Kinases
12.2K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.2K
The Equilibrium Binding Constant and Binding Strength
12.8K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
12.8K


